TEL AVIV, Israel, Mar. 2, 2018 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Companyˮ), a
clinical-stage biopharmaceutical company focused on the development
of the liver-targeted SCD1 modulator Aramchol™, a once-daily, oral
therapy for the treatment of nonalcoholic steatohepatitis, or NASH
and other liver diseases, announced today that its senior
management will provide a corporate update in upcoming investor
conferences, including the Roth 30th Annual Conference, the H.C.
Wainwright 2nd Annual NASH Investor Conference and the Oppenheimer
28th Annual Healthcare Conference.
Roth 30th Annual Conference:
Date: Monday,
March 12
Time: 2:30
pm Pacific Time
Location: GREEN
- SALON 3, The Ritz-Carlton, Laguna
Niguel, CA
H.C. Wainwright 2nd Annual NASH Investor
Conference:
Date: Monday,
March 19
Time: 10:00
am Eastern Time
Location: The
St. Regis Hotel, New York, NY
Oppenheimer 28th Annual Healthcare Conference:
Date: Tuesday,
March 20
Time: 09:45
am Estern Time
Location: Track
2 room, The Westin New York Grand Central, New York City
About Aramchol™ and Non-alcoholic Steatohepatitis
(NASH)
Aramchol™ (arachidyl amido
cholanoic acid) is a novel fatty acid bile acid conjugate, inducing
beneficial modulation of intra-hepatic lipid metabolism. Aramchol's
ability to modulate hepatic lipid metabolism was discovered and
validated in animal models, demonstrating down regulation of the
three key pathologies of NASH: steatosis, inflammation and
fibrosis. The effect of Aramchol™ on fibrosis is mediated by down
regulation of steatosis and directly on human collagen producing
cells. Aramchol™ has been granted Fast Track designation status by
the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplantation
in the U.S. due to the rise in obesity. NASH is the progressive
form of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis, liver cancer and end-stage liver
disease related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company
focused on the development of Aramchol™, a first in class, novel,
once-daily, oral therapy for the treatment of NASH for variable
populations, as well as other liver associated disorders. Galmed is
currently conducting the ARREST Study, a multicenter, randomized,
double-blind, placebo-controlled Phase 2b clinical study designed to evaluate the
efficacy and safety of Aramchol™ in subjects with NASH, who are
overweight or obese, and who are pre-diabetic or type-II-diabetic.
More information about the ARREST Study may be found on
ClinicalTrials.gov identifier: NCT02279524.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-participate-in-investor-conferences-in-march-300607138.html
SOURCE Galmed Pharmaceuticals Ltd.